Muscle-specific transcriptional machinery

The muscle-specific transcriptional machinery interacting with the MHCK7 promoter refers to the collective group of endogenous transcription factors, such as MyoD, Myogenin, and Myocyte Enhancer Factor 2 (MEF2), that bind to specific regulatory motifs within the synthetic MHCK7 promoter (Salva et al., 2007). MHCK7 is a compact, 795-base pair chimeric promoter derived from the muscle creatine kinase (MCK) gene, engineered to drive robust and specific transgene expression in both skeletal and cardiac muscle tissues (Wang et al., 2008). This machinery is not a traditional drug target for inhibition or activation; rather, it is the biological engine utilized by gene therapies like delandistrogene moxeparvovec (Elevidys) to ensure the production of therapeutic proteins, such as micro-dystrophin, occurs only in target muscle cells (Sarepta Therapeutics, 2023). By leveraging these muscle-restricted factors, the MHCK7-driven expression system minimizes the risk of off-target effects in non-muscle tissues like the liver, which is critical for reducing systemic toxicity and immune sensitization (Rodino-Klapac et al., 2013). The interaction between this machinery and the MHCK7 promoter is a fundamental component of modern neuromuscular genetic medicine, enabling the safe and effective delivery of functional genes to patients with Duchenne muscular dystrophy and other myopathies. This regulatory assembly is essential for achieving the therapeutic window necessary for clinical efficacy in systemic AAV-mediated gene delivery.

Other names

MHCK7-binding transcription factorsMuscle-specific transcription factor complexMHCK7 regulatory assembly

Binding of endogenous muscle-specific transcription factors to the synthetic MHCK7 promoter within a gene therapy vector to drive high-level, tissue-restricted transgene expression.